Corporate News back to the archivec-LEcta: European dossiers submitted for approval of new enzymes in the food industry Successful submission of two registration dossiers for food enzymes in Europe. Dossiers were prepared in exclusive collaboration with a partner in...
Leipzig, March 2, 2021 – c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, can significantly reduce the cost of supplier audits for customers thanks to its recent award of EXCiPACT certification. The certificate confirms compliance with particularly high quality standards in production and distribution. For customers from the pharmaceutical industry in particular, these standards are an important criterion for qualifying suppliers and the closure of contracts. The certification significantly eases cooperation with new and existing customers for c-LEcta. EXCiPACT certification is internationally recognized and confirms that c-LEcta complies with “Good Manufacturing Practice” and “Good Distribution Practice” for pharmaceutical excipients.
Corporate news to the archive c-LEcta continues its growth in 2020 and increases its EBITDA above average DENARASE is the most important growth driver with applications in gene and cell therapy as well as vaccine production Sales for 2020 to exceed the EUR 10 million...
Ad hoc news
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.